Empagliflozin Versus Vildagliptin in CAD Patients With T2DM
A Clinical Study Comparing Effects of Empagliflozin Versus Vildagliptin on Inflammatory Biomarkers, and Atrial Function in Coronary Artery Disease Patients With Type 2 Diabetes: EMBA-VILDA-Response Trial.
Sponsor: Damanhour University
This NA trial investigates Coronary Artery Disease and Type 2 Diabetes and is currently completed. Damanhour University leads this study, which shows 5 recorded versions since 2023 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
5 versions recorded-
Dec 2024 — Present [monthly]
Completed NA
Status: Recruiting → Completed
-
Sep 2024 — Dec 2024 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
May 2024 — Jul 2024 [monthly]
Recruiting NA
-
Apr 2024 — May 2024 [monthly]
Recruiting NA
First recorded
Aug 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Damanhour University
- Tanta University
For direct contact, visit the study record on ClinicalTrials.gov .